[Monitoring Disease Activity: How and When?]

Area of Science:

• Gastroenterology
• Immunology
• Internal Medicine

Background:

• Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition characterized by fluctuating symptoms and potential for irreversible bowel damage.
• Subclinical inflammation often persists during remission, leading to disease progression and complications like strictures or fistulae, necessitating surgical intervention in many patients.
• The treatment paradigm for IBD is shifting towards achieving mucosal healing to prevent long-term structural damage, moving beyond mere symptom control.

Purpose of the Study:

• To highlight the evolving therapeutic targets in IBD management, emphasizing mucosal healing over symptomatic relief.
• To underscore the critical need for continuous monitoring of IBD disease activity throughout the patient's disease course.
• To advocate for advanced monitoring strategies that assess disease activity beyond clinical symptoms.

Main Methods:

• Review of current IBD management strategies and therapeutic goals.
• Analysis of the limitations of symptom-based assessment in IBD.
• Discussion of the role of endoscopy, laboratory markers, and imaging in monitoring subclinical inflammation.

Main Results:

• Symptomatic control is insufficient for IBD management due to persistent subclinical inflammation.
• Mucosal healing is a more effective therapeutic target for preventing long-term intestinal damage.
• Comprehensive disease activity monitoring, including non-symptomatic indicators, is essential for optimizing IBD treatment.

Conclusions:

• Optimizing IBD therapy requires tailoring treatment to disease severity and response, necessitating regular monitoring.
• Strategies beyond symptom assessment, utilizing endoscopy, laboratory markers, and imaging, are crucial for effective IBD management.
• Proactive monitoring of subclinical inflammation is vital for preventing disease progression and improving functional outcomes in IBD patients.